Utility of Galactomannan Enzyme Immunoassay and (1,3) β- d -Glucan in Diagnosis of Invasive Fungal Infections: Low Sensitivity for Aspergillus fumigatus Infection in Hematologic Malignancy Patients
Open Access
- 1 January 2009
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 47 (1), 129-133
- https://doi.org/10.1128/jcm.00506-08
Abstract
Previous studies have reported that galactomannan (GM) enzyme immunoassay and 1,3 beta-glucan (BG) assay may be useful diagnostic tools, but their sensitivities are variable. We compared the performances of both tests. Between October 2002 and May 2005, 82 patients were prospectively monitored for 12 weeks. A total of 414 samples were tested by GM assay and 409 samples were tested by BG assay for the following four groups of patients: those with invasive aspergillosis (IA), those with other mold infections ( Fusarium , scedosporium, zygomycosis, etc.), those with candidemia, and control patients. Blood samples were obtained twice on week 1 and once every other week for a total of 12 weeks. Patients in the invasive fungal infection groups had comparable risk factors. The sensitivity of the GM test was significantly higher for patients with IA due to non- fumigatus Aspergillus species than for patients with IA due to Aspergillus fumigatus (49% versus 13%; P < 0.0001) or with other mold infections (49% versus 6%; P < 0.0001). However, the sensitivity range (47% to 64%) and specificity (88%) of the BG assay were comparable among all patients tested, regardless of the infecting pathogen. The performance of GM-based diagnosis appears to be better for detecting non- fumigatus Aspergillus species. The diagnostic marker BG was shown to have a higher sensitivity than that of GM in detecting IA and other mold infections in hematologic malignancy patients.Keywords
This publication has 34 references indexed in Scilit:
- Contribution of the (1→3)-β- d -Glucan Assay for Diagnosis of Invasive Fungal InfectionsJournal of Clinical Microbiology, 2008
- Aspergillus galactomannan testing in patients with long-term neutropenia: implications for clinical managementAnnals of Oncology, 2008
- Galactomannan and Computed Tomography-Based Preemptive Antifungal Therapy in Neutropenic Patients at High Risk for Invasive Fungal Infection: A Prospective Feasibility StudyClinical Infectious Diseases, 2005
- Antifungal Therapy Decreases Sensitivity of theAspergillus Galactomannan Enzyme ImmunoassayClinical Infectious Diseases, 2005
- Prospective clinical evaluation of lower cut‐offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipientsBritish Journal of Haematology, 2004
- Serum Glucan Levels Are Not Specific for Presence of Fungal Infections in Intensive Care Unit PatientsClinical and Vaccine Immunology, 2003
- Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioningBlood, 2003
- Contents of Volume 51Journal of Microbiological Methods, 2002
- Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International ConsensusClinical Infectious Diseases, 2002
- Incidence and risk factors for invasive fungal infections in allogeneic BMT recipientsBone Marrow Transplantation, 1997